The albumin market will reach $1.031 billion by 2023

Recently, arterial network through foreign media information learned that the United States United Market Research published an article entitled "white protein market products (human serum albumin, bovine serum albumin and recombinant albumin) and applications (therapeutics, pharmaceutical preparations and vaccines, media feeds and other applications) - Global Opportunity Analysis and Industry Forecast, 2016-2023." According to the article, the global albumin market will reach $5.94 billion in 2017 and is expected to reach $10.31 billion by 2023, with a compound annual growth rate of 9.6% from 2017 to 2023. Arterial Network compiles the article's theme:
increased burden of rare diseases and the proliferation of non-therapeutic applications is driving the growth of the albumin market. In addition, hospitals are increasingly using recombinated albumin to treat burns, shocks and blood loss, which is conducive to the development of the albumin market. However, strict government regulations and albumin-related risks limit market growth. However, opportunities that have not yet been fully developed in developing country markets and the development of cost-effective treatments will provide a profitable prospect for the market.the serum albumin portion will dominate in terms of revenue during the forecast period
due to the proliferation of treatment applications and the increase in burn patients, trauma cases, hypoproteinemia and surgery, human serum albumin revenue accounts for about three quarters of total revenue in 2017. This portion of revenue is expected to remain dominant during the forecast period. However, due to advances in the pharmaceutical industry, increased demand for albumin-based pharmaceutical preparations and vaccines, and supportive regulatory programs, the recombinant albumin market will grow at a compound annual growth rate of up to 11.4% from 2017 to 2023. The study also analyzed the bovine serum albumin market.the therapeutic application market will remain a leader during the forecast period
the therapeutic application market accounts for about half of the total market share in 2017 and will maintain its largest share in 2023. This is due to increased use of albumin in surgery, trauma, hypoproteinemia, burns, etc. However, due to the unique ability of albumin to absorb hydrophobic molecules and act as carriers of drug particles, the pharmaceutical preparation and vaccine components will grow at a compound annual growth rate of up to 10.5% between 2017 and 2023. The study also analyzed the culture base product market and other application markets.
forecast period asia-Pacific albumin market growth is the fastest
due to increased demand for albumin products, increased heart disease prevalence and the market's key players focus on the development of advanced technology products, the Asia-Pacific region will grow at a compound annual growth rate of up to 11.0% between 2017 and 2023. However, North America accounted for more than one-third of total revenue in 2017 due to the widespread adoption of recombined albumin products, a well-developed healthcare infrastructure, and the prevalence of trauma, shock, burns, liver surgery, and liver-related diseases.key players in the albumin market analyzed in the
report include China Biologics, Grifols SA, Octapharma AG, Ventria Bioscience, Shire Plc, Albumedix Ltd, CSL Limited, Thermo Fisher Scientific, Merck KGaA and Baxter International Inc. They adopt strategies such as partnerships, partnerships, mergers, acquisitions, expansions, or other means to gain a place in the industry.
note: If the article involves the arterial network reporter interview data, are provided by the interviewee and confirmed. (Arterial network)